title: Acrokeratosis paraneoplastica of Bazex as an indicator for underlying squamous cell carcinoma of the lung.
abstract: OBJECTIVE
  Obligatory cutaneous paraneoplastic disorders comprising acanthosis nigricans maligna, erythema gyratum repens, paraneoplastic pemphigus, hypertrichosis lanuginosa acquisita, erythema necrolyticum migrans and acrokeratosis paraneoplastica are rare. However, as markers of an underlying internal malignancy they are of utmost importance for the patient. Acrokeratosis paraneoplastica (first described by Gougerot and Rupp in 1922) was named after Bazex who had then reported several cases in a French dermatological journal since 1965 (Bazex et al. in Bull Soc Fr Dermatol Syphiligr 72:182, 1965; Bazex and Griffiths in Br J Dermatol 102:301-306, 1980).
  
  
  METHODS
  The study is a clinical case of a patient with acrokeratosis paraneoplastica.
  
  
  RESULTS
  the patient was later diagnosed with a cervical lymph node metastasis and thereafter with a primary squamous cell carcinoma of the left upper lobe and upon treatment responded with the clearing of the skin changes.
  
  
  CONCLUSIONS
  Identification of a paraneoplastic syndrome may enhance the earlier diagnosis of the associated tumor and may thus enable curative treatment.
authors.affiliation: Division of Hematology and Oncology, St. Georg Vorsorge- und Rehabilitationskliniken, Kurhausplatz 1, 79862 Höchenschwand, Germany. susanne.strobel@uniklinik-freiburg.de
authors.forename: Eva-Susanne
authors.initials: ES
authors.lastname: Strobel
authors.forename: Carolin
authors.initials: C
authors.lastname: Bouveret
authors.forename: Peter Karl
authors.initials: PK
authors.lastname: Kohl
mesh_terms: D001707:Biopsy, Needle; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D012008:Recurrence; D012074:Remission Induction; D012086:Reoperation; D012871:Skin Diseases / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D016896:Treatment Outcome